Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02 2024 - 4:05PM
Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage
biotechnology company pioneering the development of a new class of
programmable epigenomic mRNA medicines, today announced that
management will present at the 42nd Annual J.P. Morgan
Healthcare Conference taking place in San Francisco on Thursday,
January 11, 2024, at 9:45 a.m. PT (12:45 p.m. ET).
A live webcast of the presentation will be available on the
Investors section of the Company's website
at www.omegatherapeutics.com. An archived replay of the
presentation will be available on the same website for
approximately 90 days.
About Omega TherapeuticsOmega Therapeutics is a
clinical-stage biotechnology company pioneering the development of
a new class of programmable epigenomic mRNA medicines to treat or
cure a broad range of diseases. By pre-transcriptionally modulating
gene expression, Omega’s approach enables controlled epigenomic
modulation of nearly all human genes, including historically
undruggable and difficult-to-treat targets, without altering native
nucleic acid sequences. Founded in 2017 by Flagship Pioneering
following breakthrough research by world-renowned experts in the
field of epigenetics, Omega is led by a seasoned and accomplished
leadership team with a track record of innovation and operational
excellence. The Company is committed to revolutionizing genomic
medicine and has a diverse pipeline of therapeutic candidates
derived from its OMEGA platform spanning oncology, regenerative
medicine, multigenic diseases including immunology, and select
monogenic diseases.
For more information, visit omegatherapeutics.com, or
follow us on X and LinkedIn.
Investor Contact:
Eva Stroynowski
617.949.4370
estroynowski@omegatx.com
Omega Therapeutics (NASDAQ:OMGA)
Historical Stock Chart
From Apr 2024 to May 2024
Omega Therapeutics (NASDAQ:OMGA)
Historical Stock Chart
From May 2023 to May 2024